Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS
· Delayed Price · Currency is USD
32.13
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT
TKPHF Revenue
Takeda Pharmaceutical Company had revenue of 1.14T JPY in the quarter ending December 31, 2024, with 2.96% growth. This brings the company's revenue in the last twelve months to 4.58T, up 9.83% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical Company had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,579.02B JPY
Revenue Growth
+9.83%
P/S Ratio
1.55
Revenue / Employee
92.92M JPY
Employees
49,281
Market Cap
45.09B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Takeda Pharmaceutical Company News
- 5 days ago - How Takeda's CEO transformed the company into a global pharma powerhouse - CNBC
- 19 days ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 26 days ago - Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns - Seeking Alpha
- 6 weeks ago - Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
- 7 weeks ago - Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Benzinga
- 7 weeks ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 2 months ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - Benzinga
- 2 months ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire